Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Published:
09/05/2025
Categories:
Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access to RP1+nivolumab. We are grateful to everyone who contributed. Yesterday, along with several other melanoma organizations, we sent a letter to the FDA urging them to make RP1 available while remaining regulatory issues are addressed.
The full letter is embedded below for your reference. Click on the image to enlarge it, or download the PDF using the link beneath the letter.
Recent Posts
Apr. 27, 2026
Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event
Apr. 19, 2026
KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
Apr. 10, 2026
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
Apr. 07, 2026
2026 National Sunscreen Partner
Apr. 07, 2026